Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. NKTX
NKTX logo

NKTX

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

NKTX News

ImmunityBio Shares Triple in Three Weeks, Short-Sellers Face $500 Million Loss

Jan 21 2026Yahoo Finance

Nkarta (NKTX) Participates in Evercore 8th Annual Healthcare Conference to Showcase NK Cell Therapy Progress

Dec 02 2025Globenewswire

Nkarta to Attend Investor Conferences in November

Oct 30 2025Newsfilter

Nkarta to Present Poster at the Upcoming American College of Rheumatology (ACR) Convergence Meeting

Oct 22 2025Newsfilter

Nkarta Posts Narrower Loss in Q2

Aug 13 2025NASDAQ.COM

Needham Reiterates Buy on Nkarta, Maintains $10 Price Target

Aug 13 2025Benzinga

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

Jun 06 2025Newsfilter

Nkarta CMO David Shook Steps Down, Shawn Rose To Succeed

Jun 06 2025NASDAQ.COM

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

May 15 2025Benzinga

This Alcoa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

May 15 2025Benzinga

Needham Maintains Buy on Nkarta, Lowers Price Target to $10

May 15 2025Benzinga

Nkarta to Participate in an April Investor Conference

Apr 01 2025Yahoo Finance

Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?

Mar 27 2025Benzinga

Notable Friday Option Activity: CAR, PINS, NKTX

Dec 13 2024NASDAQ.COM

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Dec 05 2024Newsfilter

Nkarta to Participate in an Upcoming Investor Conference

Nov 26 2024Newsfilter